All News
Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed:
- rapid depletion of CD19 B cells w/ recovery by Day 90
- Days 180 and 360: returning B cells largely naive (CD27-IgD+)
- Interferon expression ↓ after CAR T treatment
@RheumNow #ACR25 https://t.co/FzdFbqWwtE
Links:
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Abstract 2695: Deep dive into B-cell depletion (BCD)
Lymph node biopsy pre/post tx:
🔹 CAR T: complete BCD + disrupted follicular architecture
🔹 RTX, OBI, BLIN: reduced BCD + preserved follicular architecture
✅ Complete LN depletion → drug-free remission
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Inflammation skews lipid levels in RA: the “lipid paradox”
Using data from CERTAIN and VARA, inflammation (hsCRP)-adjusted TC & LDL better predicted ASCVD events than standard lipids.
Are we missing RA pts who need statins?
@RheumNow #ACR25 A#2681
Jiha Lee JihaRheum ( View Tweet)
#2681 Tackling the “lipid paradox” in RA: inflammation-adjusted TC & LDL (using hsCRP correction) improved ASCVD risk prediction and flagged more high-risk patients than standard lipids. A smarter way to guide statin use in RA. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Abst 2694:
Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction
🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32
🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO
@RheumNow #ACR25 https://t.co/6CvmQ9lCfS
Links:
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657
Mrinalini Dey DrMiniDey ( View Tweet)
Lots of interest in MRI for GCA diagnosis... but what about monitoring?
Case series of 14 pts: MRI identified relapse prior to symptoms or inflammatory markers in 2 cases, including those on TCZ, which hides them
More available in US context, noninvasive, & more structures https://t.co/pnrI9SEpll
Mike Putman EBRheum ( View Tweet)
Deucravacitinib (TYK2) in PsA from POETYK trials
Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20)
Steady improvements during open label extension (all pts received drug)
Would expect approval for PsA soon... where will this fit in your approach?
@RheumNow https://t.co/325h2hf0AE
Links:
Mike Putman EBRheum ( View Tweet)
In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions increased significantly in axSpA (0.16 units/yr vs –0.02), with 15% having ≥3 lesions at 2 year vs 1% in non-axSpA. Fat lesions may signal early structural https://t.co/zvgU1Gt0po
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#ACR25 Clinical Preview by Prof Coates for use now:
GLP-1 agonist & Diet
Abstr#813 GIP/GLP-1 improved MSK pain
Abstr#849 GLP-1 reduced risk of #MACE in PsA
Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Observational study from VCRC AAV patinet, >70% had pulm involvement at some point
As expected, nodules favor GPA (63% vs 12% MPA) & DAH favors MPA (61% vs 31%)
More ILD in MPA (11% vs 1%) & more endobronchial in GPA (12% vs 2%)
Helpful pearls!
@RheumNow #ACR25 Abstr#0721 https://t.co/Iu5MdiTABR
Mike Putman EBRheum ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
GC #steroid burden & Mx
Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d
Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic
@RheumNow https://t.co/paw7NGjs4p
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing?
Turns out anything helps - get out there and don’t let perfect be the enemy of good!
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/VGH2rz3dzb
David Liew drdavidliew ( View Tweet)
Does diet matter in PsA?
Randomized study comparing advice, DASH low calorie, Mediterranean diet
Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA
Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc
David Liew drdavidliew ( View Tweet)
This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts
SSc pts had ⬆️rates of seroconversion
mean titers ⬆️ from BL
Local rxs ⬇️ in SSc pts
Systemic rxns comparable among the 2 grps
interesting data. longterm studies still needed
#ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG
Links:
sheila RHEUMarampa ( View Tweet)
Trends in Translational Abstracts content this year by Tomas Mustelin in the
“Abstracts that Will shape research in the near Future” Year in Preview session
@RheumNow #ACR25 https://t.co/i5CA8cxHeQ
Aurelie Najm AurelieRheumo ( View Tweet)
Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
Early Tx
Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr
Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
